The epidemiology of invasive fungal infections is changing, with new populations at risk and
the emergence of resistance caused by the selective pressure from increased usage of …

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …

The treatment of invasive fungal infections remains challenging due to limitations in currently
available antifungal therapies including toxicity, interactions, restricted routes of …

The cell wall is an essential component in fungal homeostasis. The lack of a covering wall in
human cells makes this component an attractive target for antifungal development. The host …

Candida species are the leading cause of invasive fungal infections worldwide and are
associated with acute mortality rates of~ 50%. Mortality rates are further augmented in the …

Several new antifungals are currently in late-stage development, including those with novel
pharmacodynamics/mechanisms of action that represent new antifungal classes …

The emergence of new fungal pathogens makes the development of new antifungal drugs a
medical imperative that in recent years motivates the talents of numerous investigators …

Fungal infections are on the rise, driven by a growing population at risk and climate change.
Currently available antifungals include only five classes, and their utility and efficacy in …

In the past three decades invasive mycoses have globally emerged as a persistent source of
healthcare-associated infections. The cell wall surrounding the fungal cell opposes the …

ABSTRACT Fosmanogepix (FMGX, APX001), a first-in-class, intravenous (iv) and oral (po)
antifungal prodrug candidate is currently in clinical development for the treatment of invasive …